- Home
- SGC vs NMRA Comparison
SGC vs NMRA Comparison
Compare SGC & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGC
- NMRA
- Stock Information
- Founded
- SGC 1920
- NMRA 2019
- Country
- SGC United States
- NMRA United States
- Employees
- SGC N/A
- NMRA N/A
- Industry
- SGC Apparel
- NMRA
- Sector
- SGC Consumer Discretionary
- NMRA
- Exchange
- SGC Nasdaq
- NMRA Nasdaq
- Market Cap
- SGC 155.7M
- NMRA 121.0M
- IPO Year
- SGC N/A
- NMRA 2023
- Fundamental
- Price
- SGC $10.76
- NMRA $0.78
- Analyst Decision
- SGC Strong Buy
- NMRA Buy
- Analyst Count
- SGC 3
- NMRA 8
- Target Price
- SGC $17.00
- NMRA $9.29
- AVG Volume (30 Days)
- SGC 56.5K
- NMRA 1.4M
- Earning Date
- SGC 08-05-2025
- NMRA 08-05-2025
- Dividend Yield
- SGC 5.17%
- NMRA N/A
- EPS Growth
- SGC N/A
- NMRA N/A
- EPS
- SGC 0.45
- NMRA N/A
- Revenue
- SGC $563,931,000.00
- NMRA N/A
- Revenue This Year
- SGC N/A
- NMRA N/A
- Revenue Next Year
- SGC $4.31
- NMRA N/A
- P/E Ratio
- SGC $24.10
- NMRA N/A
- Revenue Growth
- SGC 2.28
- NMRA N/A
- 52 Week Low
- SGC $9.11
- NMRA $0.61
- 52 Week High
- SGC $20.75
- NMRA $17.19
- Technical
- Relative Strength Index (RSI)
- SGC 61.65
- NMRA 48.23
- Support Level
- SGC $10.21
- NMRA $0.72
- Resistance Level
- SGC $11.07
- NMRA $0.85
- Average True Range (ATR)
- SGC 0.38
- NMRA 0.07
- MACD
- SGC 0.08
- NMRA -0.01
- Stochastic Oscillator
- SGC 78.32
- NMRA 23.99
About SGC Superior Group of Companies Inc.
Superior Group Of Companies Inc designs apparel products. The company's operating segment includes Branded Products; Healthcare Apparel and Contact Centers. It generates maximum revenue from the Branded Products segment. The Branded Products segment produce and sell customized merchandising solutions, promotional products and branded uniform programs to customers.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.